Content of PTX3 in the serum of patients with systemic sclerosis and corresponding significance in vasculopathy

doi:10.3969/j.issn.1004-583X.2021.04.011

Abstract

Abstract:

Objective To explore the significance of level of pentraxin 3 (PTX3) in the serum for evaluating the disease activities of patients with systemic sclerosis (SSc) and vasculopathy. Methods Thirty seven patients with SSc receiving initial therapy were selected and divided into the case group, and 31 healthy subjects were selected and divided into the control group, the case group was further divided into the disease active group and inactive group, duodenal ulcer (DU) group and non-DU group, pulmonary hypertension (PAH) group and non-PAH group, aiming to analyze the correlation between the levels of serum PTX3 , fibroblast growth factor 2(FGF2) and modified Rodnan skin scores (mRss), nailfold microcirculation test total score (NCTS) in groups. Results The level of serum PTX3 in SSc group were significantly higher than that in the control group(P<0.05),and the level off PTX3 in disease active group was higher than that in the inactive group and the control group. The levels of PTX3 and PTX3/FGF2 in DU and PAH groups were higher than those in the negative control group(P<0.05).The level of PTX3 was positively associated with NCTS, total cholesterol (CHOL) and low density lipoprotein cholesterin(LDL-G)(P<0.05). Elevated level of PTX3/FGF2 was risk factor of patients with SSc accompanying with PAH(P<0.05). Conclusion Serum PTX3 level in patients with SSc delivers certain clinical significance in determine disease activity .PTX3/FGF2 may be risk factor for patients with SSc accompanying with PAH.

Key words: scleroderma, systemic, pentraxin 3, fibroblast growth factor 2, vasculopathy

CLC Number:

R953.25

Li Hongyan, Wang Xiaoping, Yang Lin, He Jingjing, Liu Aijing. Content of PTX3 in the serum of patients with systemic sclerosis and corresponding significance in vasculopathy[J]. Clinical Focus, 2021, 36(4): 344-347.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.04.011

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I4/344

Figures/Tables 7

References 20

[1]	Desbois AC, Cacoub P. Systemic sclerosis: An update in 2016[J]. Autoimmun Rev, 2016,15(5):417-426. doi: 10.1016/j.autrev.2016.01.007 pmid: 26802722
[2]	Mantovani A, Garlanda C, Doni A, et al. Pentraxins in innate immunity: From C-reactive protein to the long pentraxin PTX3[J]. J Clin Immunol, 2008,28(1):1-13. pmid: 17828584
[3]	Cieslik P, Hrycek A. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications[J]. Autoimmunity, 2012,45:119-128. doi: 10.3109/08916934.2011.611549 URL
[4]	Bassi N, Ghirardello A, Blank M, et al. IgG anti-pentraxin3 antibodies in systemic lupus erythematosus[J]. Ann Rheum Dis, 2010,69(9):1704-1710. doi: 10.1136/ard.2009.117804 URL
[5]	Baldini M, Maugeri N, Ramirez GA, et al. Selective upregulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia[J]. Arthritis Rheum, 2012,64(3):854-865. doi: 10.1002/art.33411 URL
[6]	Kusari J, Padillo E, Zhou SX, et al. Effect of brimonidine on retinal and choroidal neovascularization in a mouse model of retinopathy of prematurity and laser-treated rats[J]. Invest Ophthalmol Vis Sci, 2011,52(8):5424-5431. doi: 10.1167/iovs.10-6262 URL
[7]	Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2013,65:2737-2747. doi: 10.1002/art.38098 URL
[8]	Valentini G, Iudici M, Walker UA, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index[J]. Ann Rheum Dis, 2017,76(1):270-276. doi: 10.1136/annrheumdis-2016-209768 URL
[9]	Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung TransPlantation (ISHLT)[J]. Eur Heart J, 2016,37(1):67-119. doi: 10.1093/eurheartj/ehv317 URL
[10]	Huang XL, Zhang L, Duan Y, et al. Association of pentraxin 3 with autoimmune diseases: A systematic review and meta-analysis[J]. Arch Med Res, 2016,47(3):223-231. doi: 10.1016/j.arcmed.2016.05.006 URL
[11]	Avouac J, Meune C, Ruiz B, et al. Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis[J]. Ann Rheum Dis, 2012,71:394-399.
[12]	Tamura Y, Ono T, Kuwana M, et al. Human Pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension[J]. Plos One, 2012,7:e45834. doi: 10.1371/journal.pone.0045834 URL
[13]	Iwata Y, Yoshizaki A, Ogawa F, et al. Increased serum pentraxin 3 in patients with systemic sclerosis[J]. J Rheumatol, 2009,36:976-983.
[14]	师永红, 王玉湘, 由江峰, 等. PI-3K和MEK1/ERK信号通路在碱性纤维母细胞生成因子诱导乳腺癌细胞低氧诱导因子活化中的作用及机制[J]. 中华医学杂志, 2004,84(22):55-59.
[15]	Leali D, Bianchi R, Bugatti A, et al. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide[J]. J Cell Mol Med, 2010,14(8):2109-2121. doi: 10.1111/jcmm.2010.14.issue-8 URL
[16]	Shirai Y, Okazaki Y, Inoue Y, et al. Elevated levels of pentraxin 3 in systemic sclerosis: Associations with vascular manifestations and defective vasculogenesis[J]. Arthritis Rheumatol, 2015,67(2):498-507. doi: 10.1002/art.v67.2 URL
[17]	高文琴, 张改连, 张莉芸. 甲襞微循环检查对系统性硬化病早期诊断和病情评估的研究进展[J]. 中华风湿病杂志, 2015,19(4):279-82, 15.
[18]	白春兰, 张军. 正五聚蛋白-3:新型心血管病炎性标志物[J]. 心血管病学进展, 2016,37(1):87-90.
[19]	Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: A modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases[J]. Trends Cardiovasc Med, 2010,20(2):35-40. doi: 10.1016/j.tcm.2010.03.005 URL
[20]	Alberti L, Gilardini L, Zulian A, et al. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors[J]. Atherosclerosis, 2009,202(2):455-460. doi: 10.1016/j.atherosclerosis.2008.05.015 pmid: 18571180

组别	例数	PTX3(ng/ml)	FGF2(pg/ml)
对照组	31	2.43(1.58)	6.17(5.23)
病例组	37	4.77(2.04)	10.77(5.07)
Z值		-4.747	-3.103
P值		0.000	0.002

组别	例数	PTX3(ng/ml)	FGF2(pg/ml)
对照组	31	2.43(1.58)	6.17(5.23)
病例组	37	4.77(2.04)	10.77(5.07)
Z值		-4.747	-3.103
P值		0.000	0.002

组别	例数	PTX3(ng/ml)	FGF2(pg/ml)
对照组	31	2.43(1.58)	6.17(5.23)
非活动组	11	3.89(2.64)^#	6.39(8.48)
疾病活动组	26	4.97(2.81)^*	10.99(4.09)^*
F值		48.354	13.237
P值		0.000	0.001

组别	例数	PTX3(ng/ml)	FGF2(pg/ml)
对照组	31	2.43(1.58)	6.17(5.23)
非活动组	11	3.89(2.64)^#	6.39(8.48)
疾病活动组	26	4.97(2.81)^*	10.99(4.09)^*
F值		48.354	13.237
P值		0.000	0.001

组别	例数	PTX3 (ng/ml)	FGF2 (pg/ml)	PTX3/FGF2
DU组	7	6.99(2.36)	11.78±6.72	723.36(435.54)
无DU组	30	4.11(2.04)	10.28±4.03	392.78(104.20)
统计值		-3.451	0.776	-3.063
P值		0.001	0.443	0.002